KAT7 promotes radioresistance through upregulating PI3K/AKT signaling in breast cancer

J Radiat Res. 2023 Mar 23;64(2):448-456. doi: 10.1093/jrr/rrac107.

Abstract

Chromatin-modifying enzymes are commonly altered in cancers, but the molecular mechanism by which they regulate cancers remains poorly understood. Herein, we demonstrated that Lysine acetyltransferase 7 (KAT7) was upregulated in breast cancer. KAT7 expression negatively correlated with the survival of breast cancer patients, and KAT7 silencing suppressed breast cancer radioresistance in vitro. Mechanistically, KAT7 activated Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) transcription, leading to enhanced PI3K/AKT signaling and radioresistance. Overexpression of AKT or PIK3CA restored radioresistance suppression induced by KAT7 inhibition. Moreover, overexpression of KAT7, but not KAT7 acetyltransferase activity-deficient mutants promoted AKT phosphorylation at the Ser473 site, PIK3CA expression and radioresistance suppression due to KAT7 inhibition. In conclusion, KAT7 has huge prospects for clinical application as a new target for predicting radioresistance in breast cancer patients.

Keywords: Lysine acetyltransferase 7 (KAT7); PI3K/AKT signaling; breast cancer; radioresistance.

MeSH terms

  • Breast Neoplasms* / radiotherapy
  • Cell Line, Tumor
  • Class I Phosphatidylinositol 3-Kinases / metabolism
  • Female
  • Histone Acetyltransferases / metabolism
  • Humans
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction

Substances

  • Proto-Oncogene Proteins c-akt
  • Phosphatidylinositol 3-Kinases
  • Class I Phosphatidylinositol 3-Kinases
  • KAT7 protein, human
  • Histone Acetyltransferases